|79.83||+2.13||+2.74%||Vol 3.85M||1Y Perf -57.19%|
|Dec 1st, 2023 16:00 DELAYED|
|- -||-0.16 -0.20%|
|Target Price||221.58||Analyst Rating||Moderate Buy 2.39|
|Potential %||177.57||Finscreener Ranking||★★★★★ 59.51|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★+ 60.30|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 86.07|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||11.17||Earnings Rating||Strong Sell|
|Market Cap||30.44B||Earnings Date||2nd Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-1.98|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.58M|
|Avg. Monthly Volume||4.23M|
|Avg. Quarterly Volume||3.95M|
Moderna Inc. (NASDAQ: MRNA) stock closed at 77.7 per share at the end of the most recent trading day (a -1.66% change compared to the prior day closing price) with a volume of 3.24M shares and market capitalization of 30.44B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1300 people. Moderna Inc. CEO is Stephane Bancel.
The one-year performance of Moderna Inc. stock is -57.19%, while year-to-date (YTD) performance is -56.74%. MRNA stock has a five-year performance of %. Its 52-week range is between 62.55 and 217.25, which gives MRNA stock a 52-week price range ratio of 11.17%
Moderna Inc. currently has a PE ratio of 3.30, a price-to-book (PB) ratio of 3.85, a price-to-sale (PS) ratio of 5.15, a price to cashflow ratio of 11.50, a PEG ratio of 0.49, a ROA of 50.09%, a ROC of 77.98% and a ROE of 83.69%. The company’s profit margin is 50.25%, its EBITDA margin is 66.30%, and its revenue ttm is $13.73 Billion , which makes it $35.73 revenue per share.
Of the last four earnings reports from Moderna Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.98 for the next earnings report. Moderna Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Moderna Inc. is Moderate Buy (2.39), with a target price of $221.58, which is +177.57% compared to the current price. The earnings rating for Moderna Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Moderna Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Moderna Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.14, ATR14 : 3.59, CCI20 : 76.66, Chaikin Money Flow : 0.25, MACD : -1.64, Money Flow Index : 47.44, ROC : 10.92, RSI : 46.79, STOCH (14,3) : 74.67, STOCH RSI : 0.29, UO : 51.85, Williams %R : -25.33), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Moderna Inc. in the last 12-months were: AFEYAN NOUBAR (Sold 165 000 shares of value $18 233 563 ), Arpa Garay (Option Excercise at a value of $0), Bancel Stephane (Option Excercise at a value of $1 531 683), Bancel Stephane (Option Exercise at a value of $26 883), Bancel Stephane (Sold 1 574 310 shares of value $219 185 506 ), Berenson Stephen (Option Excercise at a value of $0), Hoge Stephen (Option Excercise at a value of $0), Hoge Stephen (Sold 34 497 shares of value $4 171 764 ), James Mock (Sold 0 shares of value $0 ), James Mock (Sold 2 858 shares of value $292 945 ), Juan Andres (Option Excercise at a value of $167 440), Juan Andres (Sold 8 000 shares of value $1 497 720 ), Klinger Shannon (Option Excercise at a value of $0), Klinger Shannon (Sold 1 695 shares of value $226 455 ), Klinger Shannon Thyme (Sold 110 shares of value $14 336 ), Shannon Thyme Klinger (Option Excercise at a value of $0), Shannon Thyme Klinger (Sold 1 510 shares of value $229 794 ), Stephane Bancel (Option Excercise at a value of $1 306 800), Stephane Bancel (Sold 1 370 000 shares of value $237 716 464 ), Stephen Hoge (Option Excercise at a value of $0), Stephen Hoge (Sold 1 317 shares of value $188 119 )
Tue, 21 Nov 2023 16:06 GMT Moderna tells Reuters will appeal European Patent Office decision- TipRanks. All rights reserved.
Fri, 03 Nov 2023 09:01 GMT Analysts Offer Insights on Healthcare Companies: Zoetis (ZTS), Moderna (MRNA) and Regeneron (REGN)- TipRanks. All rights reserved.
Thu, 02 Nov 2023 14:06 GMT Moderna (MRNA) Receives a Buy from UBS- TipRanks. All rights reserved.
Tue, 22 Aug 2023 13:55 GMT Early notable gainers among liquid option names on August 22nd- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.